Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$45.41 USD
-1.28 (-2.74%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $45.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 281 - 300 ( 310 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Transferring Coverage
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
AG-120, Active in IDH1m Solid Tumors, But is it Active Enough?
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Awaiting Clarity from AG-120 and AG-348 Before Getting Constructive
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Focus Now on the Upcoming EHA Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
IDH Programs Positioned to be the Next Standard-of-Care in IDHm-AML
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.